Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-05-14

Clinical Trial Update: Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating fulvestrant in combination with enzalutamide for ER+/HER2- advanced breast cancer has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Enzalutamide (enzalutamide)
  • Fulvestrant (fulvestrant)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-05-14